Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 4/20 | 0.38 |
| ▸ | BCL2 | P10415 | 5/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498346 | 0.93 | CD274 (0.37) | PIK3C2BBCL2MCL1ALOX5APCD274 | |
| SCHEMBL6500643 | 0.93 | ALOX5AP (0.40) | PIK3C2BBCL2MCL1ALOX5APPTGES | |
| SCHEMBL6502905 | 0.93 | PIK3C2B (0.41) | PIK3C2BBCL2MCL1ALOX5APPTGES | |
| SCHEMBL6500738 | 0.90 | PIK3C2B (0.38) | PIK3C2BBCL2MCL1ALOX5APPTGES | |
| SCHEMBL6501134 | 0.88 | BCL2 (0.47) | PIK3C2BBCL2MCL1DHODHPLA2G2A | |
| SCHEMBL6487419 | 0.88 | DCTPP1 (0.42) | PIK3C2BBCL2MCL1ALOX5APDCTPP1 | |
| SCHEMBL6492529 | 0.87 | PIK3C2B (0.38) | PIK3C2BBCL2MCL1ALOX5APCD274 | |
| SCHEMBL6496471 | 0.87 | DCTPP1 (0.37) | PIK3C2BBCL2MCL1ALOX5APCD274 | |
| SCHEMBL6501228 | 0.85 | BCL2 (0.40) | PIK3C2BBCL2MCL1ALOX5APDHODH | |
| SCHEMBL6488013 | 0.85 | BDKRB1 (0.36) | PIK3C2BBCL2MCL1ALOX5APDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PIK3C2B 2433/4885BCL2 774/4885MCL1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.